Introduction
The gastrointestinal tract is the most common site of malignancies of any anatomic system in the body (Seregni et al., 2001 ); every year an estimated 2.5 million people are newly diagnosed (Boyle and Levin, 2008; Jemal et al., 2011) . Gastrointestinal tumors are often diagnosed at late stages since patients with gastrointestinal tumors have a very broad range of dyspeptic symptoms. Therefore, the determining of sensitive and specific molecular markers can be a useful clinical tool for the early detection and management of diseases (Plaks et al., 2013) . Because of the heterogeneity of gastrointestinal tumors, a panel of biomarkers for screening and diagnosis would be the most appropriate (Lurje et al., 2010) . Recently published studies showed that detection of elevated circulating tumor cells (CTCs) was a prognostic factor for metastatic gastrointestinal cancers as well as an accurate indication of rapid progression and mortality (Rahbari et al., 2010; Rhim et al., 2012) .
Detection of tumor cells in the blood could lead to a search for epithelial-specific mRNAs, which might be revealed in patients' blood samples via amplification by reverse transcription-polymerase chain reaction (RT-PCR). The use of RT-PCR allows sensitive and reliable detection of a very small number of circulating tumor cells in blood or bone marrow. RT-PCR assays using epithelial markers are based on the principle that carcinoma cells detach from the site of the primary tumor and are distributed to hematopoietic or lymphatic tissue (Alix-Panabières and Pantel, 2013) . This can lead to the appearance of gene transcripts that are not normally expressed in these host tissues Tsouma et al., 2008) .
Cytokeratins (CKs) such as CK19 and CK20 are generally used for the detection of most epithelial tumors and they belong to the epithelial subgroup of the intermediate filament protein family that is involved in cell structure and differentiation. Expression studies showed that CK19 expressed in all epithelial cells; however, CK20 is restricted to gastrointestinal epithelium, urothelium, and Merkel cells and this profile is maintained in malignant tumors of these cells. The malignant nature of CK-positive cells in the bone marrow has been confirmed through genomic analysis using fluorescence in situ hybridization (Muller et al., 1996; Stathopoulou et al., 2002) . The relatively specific expression of CKs by epithelial tissues and conservation of this cell specificity following malignant transformation has led to their widespread use as reliable markers for diagnostic pathology.
Understandably, CKs have served as the most widely used target for detection of metastasis from epithelial-derived tumors in a variety of sites (Wlyd, 1998) .
Tumor-associated protein mucin 1 (MUC1) is also very often used to trace metastatic cancer cells in gastrointestinal cancer (Uen et al., 2006; Lagoudianakis et al., 2009) . Mucins are involved in a variety of physiologic functions including protection against mechanical and infectious insults, lubrication, and acid resistance. An increased expression of MUC1 in human and colorectal cancer as a marker of progression and metastasis was demonstrated previously (Nakamori et al., 1994; Baldus et al., 2004) . Telomerase, an enzyme responsible for continuous cell growth, is repressed in most somatic cells but activated in approximately 85% of human cancer tissues (Hiyama and Hiyama, 2003) . There were several reports that human telomerase reverse transcriptase (hTERT) mRNA is present in the peripheral blood of patients with some cancer types (Chen et al., 2000; Shin et al., 2002; Wang et al., 2006) .
The current study aimed to evaluate the feasibility of detection of MUC1, CK20, and hTERT mRNAs in the peripheral blood of gastrointestinal cancer patients based on RT-PCR amplification.
Materials and methods

Subjects
A total of 61 peripheral blood samples from 31 pathologically confirmed gastrointestinal cancer patients and 30 healthy subjects were collected from the Department of Gastroenterology of the Gülhane Military Medical Academy Hospital. The study was conducted in compliance with the Helsinki Declaration and it was approved by the institutional ethics committee; all patients and healthy subjects involved gave their written informed consent.
Clinicopathologic characteristics of the study population are summarized in Table 1 . All patients suffered from adenocarcinomas. Clinical stages and pathologic features of primary tumors were defined according to the criteria of the American Joint Commission of Cancer (Greene et al., 2001 ). All patients with gastrointestinal cancer were found to have no evidence of other disease. Ten milliliters of peripheral blood was drawn into an EDTA tube and stored at 4 °C. As a positive control, RNA samples were also prepared from the human colon cancer cell line HT-29 (a gift from Dr G Selmanoğlu, Hacettepe University, Ankara, Turkey). 2.2. Total RNA isolation and cDNA synthesis Blood tubes were centrifuged at 1000 × g for 5 min; the buffy coat was collected and transferred into 1.5-mL Eppendorf tubes. Total RNA extraction was performed using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions and the product was stored at -80 °C until use. To avoid contamination of DNA within RNA preparation, 1 µg of RNA was treated with RNase-free DNase I, as recommended by the supplier (New England BioLabs, Hitchin, UK). The first-strand cDNA was synthesized from total RNA by using MuLV reverse transcriptase (New England BioLabs). Total RNA (1 µg) was reverse-transcribed in a final volume of 50 µL containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM DTT, 0.2 mM oligo(dT) 15 , 0.2 mM dNTPs, and 100 U of MuLV reverse transcriptase according to the manufacturer's guidelines.
The reaction mixtures with RNA were incubated at 42 °C for 1 h, heated to 95 °C for 5 min, and then stored at -20 °C until analysis.
PCR amplification
The quantity of isolated RNA was confirmed by amplification of cDNA for house-keeping gene GAPDH. Each PCR reaction mixture contained 1X PCR buffer [67 mM Tris-HCl (pH 8.3), 16 mM (NH 4 ) 2 SO 4 , 0.1% Tween-20, 2.5 mM MgCl 2 ], 0.1 mM dNTP, 0.1 µM sense and antisense primers for target genes, and 1 U Taq DNA polymerase (Bioron, Ludwigshafen am Rhein, Germany) in a total volume of 25 µL. PCR products were analyzed in 2.5% agarose gel. The signals on UV transilluminator for each target gene and GAPDH expression levels were analyzed with a computing densitometer (Syngene GeneTools software) to calculate the relative mRNA density ratio. The primer sequences, PCR conditions, and predicted product size are given in Table 2 .
Sequencing of PCR products
The amplified PCR products were sequenced using a Big Dye sequencing system (Applied Biosystems, Carlsbad, CA, USA) and determined to be identical to those expected. 
Statistical analysis
All analyses were conducted with SPSS 19. Potential association between the expression of molecular markers used in combination and the clinicopathologic features of the study subjects were evaluated using 2 × 2 or 2 × k contingency tables and the significance of these comparisons was assessed using 2-tailed Fisher's exact tests.
To evaluate the usefulness of gene expression levels and presence/absence data of the 3 mRNA markers for predicting overall tumor presence, metastasis status, and colorectal tumor presence, we conducted separate logistic regression analysis. Tumor presence, metastasis status, and colorectal tumor presence were taken as binary dependent variables and coded using 0 (absence of tumor or metastasis) and 1 (presence of tumor or metastasis) as dummy variables Significant fit of the regression equation to the data was assessed using Wald statistics; however, the cut-off for statistical significance was taken as P < 0.008 after Bonferroni correction for multiple comparisons. We also calculated odds ratios (ORs) determining the strength of association between predictive markers and tumor presence.
Receiver operating characteristic (ROC) curve analyses were done to analyze the RT-PCR data of MUC1, CK20, and hTERT gene expression in the peripheral blood of the subjects. The area under the ROC curve and the corresponding 95% confidence intervals (95% CI) were calculated for each marker. The cut-off value at the highest accuracy level (minimal false-negative and false-positive results) was determined.
Results
Expression of MUC1, CK20, and hTERT mRNAs in peripheral blood samples from gastrointestinal cancer patients
In analysis of the peripheral blood, 77.4% (24/31), 61.29% (19/31), and 45.16% (14/31) of cancer patients were positive for MUC1, CK20, and hTERT mRNAs, respectively. Seven (22.58%) of 31 patients were positive for all 3 mRNAs. The sensitivity and specificity for any one of the mRNAs detected in peripheral blood is 90.32% and 53.3%, respectively, with an accuracy of 68.85% (Table 3) .
We used 2-tailed Fisher's exact tests to analyze the potential association between the expression of molecular markers used in combination and the clinicopathologic features of the study subjects. No association was found between the presence of mRNA markers and clinicopathologic characteristics of patients (Table 4) .
For the 3 mRNA markers that we detected, there were no differences between patients with different stages (P > 0.05). Our results showed that combined analysis of MUC1 and CK20 helps to decrease the false-positive rate of detection (Table 3) .
The predictive values of the 3 mRNA markers for tumor presence were analyzed using univariate logistic regression analysis (Tables 5 and 6 ). According to our results, any one of these mRNA markers is a predictor of the presence of gastrointestinal tumors (P < 0.001) and colorectal tumors (P < 0.05). These markers do not have predictive value for presence of metastasis in gastrointestinal tumors (Table 7) .
ROC curve analyses of the RT-PCR data of the 61 subjects (31 cancer patients and 30 healthy individuals) , CK20 expression in 6 (20%), and hTERT expression in 4 (13.3%) samples. The positive ratios of MUC1, CK20, and hTERT mRNAs in gastrointestinal cancer patients are significantly higher than in healthy subjects (Table 3) .
Discussion
Developments in biotechnology have made it possible to detect small numbers of tumor cells in peripheral blood, and these cells would provide a useful monitoring, diagnostic, and prognostic tool (Bednarz-Knoll et al., 2011; Wicha and Hayes, 2011) . In recent years, there have been many reports on the RT-PCR detection of CTCs in the peripheral blood, bone marrow, and/or peritoneal lavage of patients with gastrointestinal cancer (Pantel et al., 1999; Yamaguchi et al., 2000; Stathopoulou et al., 2002; Gradilone et al., 2003; Dandachi et al., 2005; Uen et al., 2006) . Compared with bone marrow and lymph nodes, blood collection is a minimally invasive procedure and blood can be sampled throughout the course of the disease (Böckmann et al., 2001; Huang et al., 2003; Pantel and Alix-Panabières, 2010; Bednarz-Knoll et al., 2011) .
Because of the heterogeneity of gastrointestinal tumors, a panel of biomarkers could enhance the sensitivity of CTC detection compared with the single markers in use (Conzelmann et al., 2005; Lurje et al., 2010) . The aim of this work was to evaluate the feasibility of detection of CTCs in the peripheral blood of gastrointestinal cancer patients based on the RT-PCR amplification of MUC1, CK20, and hTERT mRNAs, aiming to use a standardized PCR method according to the World Health Organization criteria for a screening test: acceptability, practicability, high specificity, and high sensitivity (Kramer at al., 1999) .
To evaluate the presence and predictive value of MUC1, CK20, and hTERT in the peripheral blood of gastrointestinal cancer patients, we analyzed 3 markers in 31 cancer patients and 30 healthy individuals, and we explored the correlation between expression of these markers and tumor presence.
Because of its high sensitivity, RT-PCR based on the amplification of the cell type-specific mRNA is increasingly used to detect CTCs. In previous studies, many target genes have been used to detect CTCs in gastrointestinal carcinoma, such as CEA, MUC1, hTERT, cMet, CK18, CK19, and CK20 (Soeth et al., 1997; Yamaguchi et al., 2000; Katsumata et al., 2006; Uen et al., 2006; Wu et al., 2006; Xi et al., 2007; Tsouma et al., 2008; Lagoudianakis et al., 2009) . Cytokeratins are frequently used to detect the CTCs in peripheral blood (Weitz et al., 1999; Gradilone et al., 2003; Wang et al., 2006; Wang et al., 2007) . The mRNAs of CK19 and CK20 have been successfully used to detect CTCs in the peripheral blood of patients with breast cancer, lung cancer, and gastrointestinal carcinoma (Mori et al., 1996; Denis et al., 1997; Peck et al., 1998) . Wlyd et al. (1998) suggested that CK20 may be a useful target for RT-PCR detection of epithelial-derived cancers than previously described in cytokeratins.
In our study, in RT-PCR analysis of the peripheral blood, 77.4% (24/31), 61.29% (19/31), and 45.16% (14/31) of cancer patients were positive for MUC1, CK20, and hTERT mRNAs, respectively. When combining MUC1, CK20, and hTERT mRNA markers for the detection of CTCs in gastrointestinal cancer patients, the sensitivity of the detection rate increased up to 90.32% (28/31) and the rate of false positives was 3.33% (1/30). No correlation was found between the presence of MUC1, CK20, and hTERT (Table 4) . In this study, in RT-PCR analysis of the peripheral blood of cancer patients and healthy individuals, 100% (61/61) were positive for CK19. Due to the high false-positive rate, CK19 is not useful for CTC detection. Similarly to our results, other investigators have also detected CK19 transcripts in the peripheral blood of healthy individuals (Krismann et al., 1995; Stathopoulou et al., 2002; Wu et al., 2006) . The false positive in healthy individuals might be attributed to the design of primers, pseudogenes, contamination of epithelial cells, or the handling of samples (Ruud et al., 1999; Wang et al., 2006; Tsouma et al., 2008) . These may involve the ectopic expression of the CK19 gene in hematopoietic cells or the expression of any gene in any cell type (Chelly et al., 1989; Novaes et al., 1997; Stathopoulou et al., 2002) . In the literature, different frequencies for MUC1, CK20, and hTERT in patients have been described (Noguchi et al., 1996; de Cremoux et al., 2000; Katsumata et al., 2006; Uen et al., 2006) . The differences could be explained by the heterogeneous designs of these studies (number of samples, sampling methods, tumor sites, tumor stages, RNA extraction, and PCR protocols). Improved sensitivity in patients may be achieved by analysis of larger blood volumes and analysis of multiple samples from one individual. This method may reduce false-negative results (Wlyd et al., 1998) . Jonas et al. (1997) reported an increased rate of CEA detection by RT-PCR in peripheral blood samples from patients with colorectal cancer when 3 separate samples were analyzed. CTC detection methods also need to be taken into account, as sensitivity and specificity are of major importance and may differ significantly. Thus, it will be important to define the critical variables in the methods and to introduce at least some level of standardization to allow for more reliable and reproducible results (Pantel et al., 1999; Vlems et al., 2002; Uen et al., 2006; Khair et al., 2007) .
In our study, we found that MUC1, CK20, and hTERT mRNAs are significantly more frequently detected in gastrointestinal cancer patients than in healthy controls and could serve as markers. Funaki et al. (1998) detected CK20 mRNA in the peripheral blood of advanced colorectal carcinoma patients, which seems to present an indicator of possible recurrence in individual patients. It has been suggested that CK20 mRNA detection by RT-PCR in the peripheral blood and bone marrow is a promising marker for circulating tumor cells of epithelial origin Johnson et al., 1995; Soeth et al., 1997; Katsumata et al., 2006) .
In the univariate analysis, there was statistically significant association between the detection of any one mRNA and tumor presence (P < 0.001). These results clearly demonstrate the significant and prognostic/ predictive value of MUC1, CK20, and hTERT mRNA detection by RT-PCR in the peripheral blood of patients with gastrointestinal cancers. Similar to our results, Msaouel and Koutsilieris (2011) reported that CTC evaluation can confirm tumor diagnosis.
Other studies showed MUC1, CK20, and hTERT expressions in peripheral blood of healthy individuals (de Cremoux et al., 2000; Gradilone et al., 2003; Uen et al., 2006; Wu et al., 2006; Wang et al., 2007) . Illegitimate transcription of tissue-specific genes in blood from healthy individuals has been previously described by the mononuclear fraction. Sources of illegitimate expression of MUC1, CK20, and hTERT mRNAs are macrophages, lymphocytes, and hematopoietic cells. Illegitimate transcription in blood cells is a well-known limitation and lowers the specificity of the RT-PCR analysis. While using RT-PCR in CTC detection could overcome the problems of lack of sensitivity associated with other methods, the selection of epithelial-specific mRNA is difficult (Solmi et al., 2006) .
Our study demonstrated that MUC1, CK20, and hTERT gene expressions differ between individuals even if they have the same tumor type. Therefore, marker combinations maximize differences in expression in tumors compared with cells isolated from normal blood. Due to the heterogeneity of the expression of tumor-related genes, a multimarker assay is regarded as more reliable and sensitive than a single marker assay (Conzelmann et al., 2005; Lurje et al., 2010) .
In this study, we found that the detection of MUC1, CK20, and hTERT mRNAs in the peripheral blood of patients with gastrointestinal cancers is a significant predictive/prognostic factor for determining tumor presence. This method could offer a simple, noninvasive, and promising tool for the detection of CTCs. However, a further study in larger patient and healthy populations is required to confirm the clinical usefulness of these molecular markers. Moreover, in order to arrive at a highly significant conclusion, a further study is to be performed with a particular tumor type, such as focusing on the stomach.
